Ken Griffin
STLN

Ken Griffin’s Starling Oncology, Inc. Common Stock STLN Stock Holding History

Ken Griffin’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.87M Buy
+608,267
New +$1.87M ﹤0.01% 6215
2025
Q4 		– Sell
-14,961
Closed -$55.5K – 14077
2025
Q3 		$52.2K Buy
+14,961
New +$51.3K ﹤0.01% 12180
2024
Q4 		– Sell
-91,337
Closed -$29.9K – 15399
2024
Q3 		$29.9K Sell
91,337
-178,367
-66% -$73.9K ﹤0.01% 12445
2024
Q2 		$124K Buy
269,704
+239,558
+795% +$204K ﹤0.01% 10616
2024
Q1 		$47.6K Sell
30,146
-113,694
-79% -$216K ﹤0.01% 12217
2023
Q4 		$293K Buy
143,840
+101,123
+237% +$175K ﹤0.01% 9200
2023
Q3 		$59.8K Buy
+42,717
New +$44.2K ﹤0.01% 11544
2022
Q2 		– Sell
-60,387
Closed -$431K – 14109
2022
Q1 		$431K Buy
60,387
+20,826
+53% +$140K ﹤0.01% 9742
2021
Q4 		$386K Sell
39,561
-1,427,623
-97% -$12.7M ﹤0.01% 10310
2021
Q3 		$14.6M Buy
+1,467,184
New +$14.6M ﹤0.01% 2460
2021
Q2 		– Sell
-14,448
Closed -$144K – 14445
2021
Q1 		$144K Buy
+14,448
New +$154K ﹤0.01% 12096

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ken Griffin's STLN Position: Q1 2026 in Review

Ken Griffin opened a new position in Starling Oncology, Inc. Common Stock (STLN) in Q1 2026: 608,267 shares worth $1.87M. The stake represents ﹤0.01% of the portfolio and ranks #6215 among its holdings. This is a return to the name: Ken Griffin previously reported a position in STLN as recently as Q3 2025.

Ken Griffin first reported a position in STLN in Q1 2021 and has held it in 11 quarters since. The position peaked at $14.6M in Q3 2021. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Ken Griffin held 608,267 shares of Starling Oncology, Inc. Common Stock worth $1.87M as of Q1 2026.
  • Starling Oncology, Inc. Common Stock was a new Ken Griffin position in Q1 2026.
  • Starling Oncology, Inc. Common Stock made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6215 holding.
  • Ken Griffin first reported a position in Starling Oncology, Inc. Common Stock in Q1 2021 and has held it in 11 quarters since.
  • Ken Griffin's Starling Oncology, Inc. Common Stock position peaked at $14.6M in Q3 2021.
  • 115 funds tracked by Wall St. Rank held Starling Oncology, Inc. Common Stock as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.